The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 05, 2023
Filed:
Apr. 20, 2021
Applicant:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Inventors:
Jiaxi Wu, Elmsford, NY (US);
Tong Zhang, New Rochelle, NY (US);
Samuel Davis, New York, NY (US);
Nicolin Bloch, Ossining, NY (US);
Assignee:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/55 (2006.01); A61K 38/20 (2006.01); A61K 45/06 (2006.01); C07K 14/47 (2006.01); C07K 14/735 (2006.01); C07K 14/74 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/55 (2013.01); A61K 38/2013 (2013.01); A61K 45/06 (2013.01); C07K 14/4748 (2013.01); C07K 14/70535 (2013.01); C07K 14/70539 (2013.01); A61K 38/00 (2013.01); C07K 2319/21 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/41 (2013.01);
Abstract
This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2Rα. The IL-2 variants may retain the ability in binding to or activating IL-2Rβ and/or IL-2Rβγ. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.